Recent Quotes
My Watchlist
Indicators
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.44 -1.05 (-4.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,665,896
Open 26.90
Bid (Size) 16.00 (100)
Ask (Size) 27.25 (5,000)
Prev. Close 25.49
Today's Range 23.47 - 27.13
52wk Range 18.80 - 27.64
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release ↗
Pacira BioSciences, a leader in non-opioid pain management, reported a notable insider sale amid ongoing option exercise activity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pacira (PCRX) Q1 2026 Earnings Call Transcript ↗
Pacira (PCRX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
-0.1%
-0.1%
1 Month
+8.1%
+8.1%
3 Month
+21.7%
+21.7%
6 Month
+14.9%
+14.9%
1 Year
-9.1%
-9.1%

More News

Read More
Pacira Biosciences (NASDAQ:PCRX) Q1 2026 Results Beat Estimates as Key Pipeline Catalysts Near ↗
Via Chartmill
News headline image
Pacira BioSciences Reports First Quarter 2026 Financial Results
From Pacira BioSciences
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Presents a Compelling Value Investment Case ↗
Via Chartmill
Pacira BioSciences Inc (NASDAQ:PCRX) Misses Q4 Earnings and Revenue Estimates, Shares Drop ↗
Via Chartmill
News headline image
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
From Pacira BioSciences
Via GlobeNewswire
News headline image
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
From Pacira BioSciences
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
Via MarketMinute
News headline image
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira (PCRX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
From Pacira BioSciences
Via GlobeNewswire

Frequently Asked Questions

Is Pacira BioSciences, Inc. - Common Stock publicly traded?
Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.
What exchange does Pacira BioSciences, Inc. - Common Stock trade on?
Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?
The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market
What is the current price of Pacira BioSciences, Inc. - Common Stock?
The current price of Pacira BioSciences, Inc. - Common Stock is 24.44
When was Pacira BioSciences, Inc. - Common Stock last traded?
The last trade of Pacira BioSciences, Inc. - Common Stock was at 05/01/26 04:00 PM ET
What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?
The market capitalization of Pacira BioSciences, Inc. - Common Stock is 1.09B
How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?
Pacira BioSciences, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>